Is InnoCare Pharma (SEHK:9969) Still Undervalued After Its First Bispecific ADC Trial Approval?

InnoCare Pharma (SEHK:9969) just received clearance from China’s Center for Drug Evaluation to begin clinical trials for ICP-B381, its first bispecific antibody drug conjugate targeting PSMA and STEAP1 in prostate cancer.

The IND approval lands after a strong run in InnoCare Pharma’s share price, with a 90-day share price return of 44.82% and a 1-day move of 14.55% taking the stock to HK$15.51. However, the 1-year total shareholder return is still down 12.91%, while the 3-year total shareholder return is up 155.10%, which points to momentum rebuilding recently after a tougher stretch for longer term holders.

Capitalize on the renewed interest in InnoCare Pharma by scanning a curated set of biopharma peers with resilient balance sheets and cleaner fundamentals through our list of solid balance sheet and fundamentals (194 results).

After a sharp rebound in InnoCare Pharma and fresh clinical momentum from ICP-B381, the question now is simple: Does the current price still offer a favourable risk reward, or has most of the easy upside been used up already?

Most Popular Narrative: 21% Undervalued

On Simply Wall St's most followed narrative, InnoCare Pharma screens as undervalued, with a fair value of HK$19.62 against the last close of HK$15.51. That gap rests on a view that the current pipeline and autoimmune portfolio can support higher long term cash flows than the share price implies.

The company has a strong pipeline with numerous drugs in late-stage development, including tafasitamab, zurletrectinib, and others, expecting approvals and launches in the next few years, which could significantly bolster future revenues.

The introduction of InnoCare's ADC platform aims to tap into new therapeutic areas with highly differentiated products, potentially opening new revenue streams and improving net margins through innovative therapies with a better safety profile.

See why 1 investors see InnoCare Pharma as 21% undervalued.

Result: Fair Value of HK$19.62 (UNDERVALUED)

Still, the story can break if R&D spending fails to convert into commercial products or if rivals pressure pricing on orelabrutinib and newer assets.

Find out about the key risks to this InnoCare Pharma narrative.

Another View: InnoCare Pharma On Earnings-Based Pricing

There is a catch. While the DCF work flags InnoCare Pharma as cheap against its cash flow potential, the P/E snapshot paints a richer picture, with the stock on 24.5x earnings compared with a fair ratio of 9.7x and an industry average of 17.4x. Is that gap a cushion or a warning sign for you?

To stress test that earnings-based view against your own expectations for the pipeline and margins, check the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown..

For a quick visual on how InnoCare Pharma is priced against peers on earnings today, review the relative chart in

.

Next Steps

Mixed signals on InnoCare Pharma so far. If you want to move quickly and base your decision on more than headlines, start by weighing the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond InnoCare Pharma?

Do not stop at InnoCare Pharma. Broaden your watchlist with fresh ideas that combine quality, resilience and income potential before the next wave of opportunities gets priced in.

• Target potential mispricing by scanning a curated pool of quality companies that look cheap on fundamentals through the 188 high quality undervalued stocks.
• Build a steadier portfolio foundation by focusing on businesses with strong finances using the 103 resilient stocks with low risk scores.
• Add income-focused candidates to your radar by zeroing in on higher yielding opportunities in the 162 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com